Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.

ABSTRACT:

SUBMITTER: Karimi L 

PROVIDER: S-EPMC10259662 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature